korean
porcin
emcv
strain
isol
monoclon
antibodi
mab
protein
use
describ
previous
spodoptera
frugiperda
insect
cell
maintain
grace
medium
invitrogen
usa
contain
fetal
bovin
serum
gibco
usa
lactalbumin
hydrolys
gibco
usa
antibioticsantimycot
solut
gibco
usa
infect
cell
maintain
sf
ii
sfm
gibco
usa
without
fetal
bovin
serum
gene
capsid
protein
nonstructur
protein
proteas
amplifi
clone
htb
invitrogen
usa
describ
previous
gene
insert
stream
polyhedron
promot
pph
recombin
baculoviru
gener
sitespecif
transposit
baculoviru
shuttl
vector
bacmid
propag
cell
invitrogen
usa
use
bac
bac
baculoviru
express
system
invitrogen
usa
accord
manufactur
instruct
recombin
baculoviru
plaqu
purifi
presenc
gene
confirm
pcr
use
previous
describ
primer
set
cell
cultur
plate
infect
recombin
baculoviru
multipl
infect
moi
h
vero
cell
infect
grown
cultur
plate
posit
control
express
recombin
protein
analyz
immunofluoresc
assay
ifa
western
blot
analysi
previous
describ
cell
flask
infect
recombin
baculoviru
moi
harvest
day
postinfect
dpi
harvest
cell
clarifi
centrifug
concentr
use
polyethylen
glycol
precipit
load
onto
wv
discontinu
sucros
step
densiti
gradient
describ
previous
peak
fraction
sucros
gradient
allow
settl
glowdischarg
carbonco
grid
morpholog
examin
transmiss
electron
microscopi
tem
tecnai
korea
basic
scienc
institut
grid
blot
dri
stain
uranyl
acet
sampl
visual
use
transmiss
electron
microscop
magnif
femal
balbc
mice
age
week
use
immun
challeng
trial
mice
randomli
divid
four
group
fifteen
mice
group
group
intramuscularli
im
inocul
ml
antigen
two
time
interv
week
group
inocul
pb
neg
control
group
inocul
commerci
kill
vaccin
choongang
vaccin
laboratori
korea
posit
control
group
group
inocul
respect
crude
protein
extract
infect
cell
contain
vlp
day
postvaccin
ten
mice
group
challeng
intramuscularli
ml
strain
contain
per
mous
remaind
group
analyz
humor
immun
respons
describ
previou
twelv
pig
weigh
approxim
kg
antibodi
neg
emcv
separ
six
group
two
pig
antigen
mix
equal
volum
montandid
im
n
vg
seppic
franc
group
inocul
intramuscularli
ml
antigenadjuv
mixtur
group
inocul
pb
neg
control
group
inocul
commerci
vaccin
posit
control
group
group
inocul
crude
protein
respect
extract
infect
cell
contain
vlp
group
group
inocul
twice
week
interv
respect
crude
protein
extract
infect
cell
contain
vlp
immun
swine
observ
min
monitor
clinic
sign
immun
period
day
interv
sera
collect
everi
week
day
immun
swine
analyz
seroconvers
neutral
emcv
antibodi
detect
collect
sera
use
vitro
neutral
assay
describ
previou
result
neutral
antibodi
level
present
mean
sem
signific
variabl
among
experiment
group
determin
twoway
anova
probabl
valu
p
consid
signific
cell
transfect
bacmid
contain
gene
recombin
baculovirus
identifi
plaqu
assay
confirm
pcr
data
shown
cell
infect
moi
cell
supernat
harvest
analyz
dpi
point
cell
show
cytopath
effect
cpe
ifa
cell
infect
react
mab
exhibit
strong
cytoplasm
stain
figur
western
blot
show
specif
protein
predict
size
kda
observ
vero
cell
strain
cell
infect
figur
examin
whether
cell
infect
gener
viruslik
particl
cell
infect
prepar
visual
tem
seen
figur
hollow
spheric
shape
structur
diamet
nm
identifi
cell
wherea
structur
observ
uninfect
sf
cell
data
shown
serum
sampl
collect
immun
mous
group
day
second
immun
neg
control
group
immun
pb
group
neg
neutral
antibodi
wherea
group
immun
commerci
vaccin
produc
virusneutr
antibodi
high
level
fold
group
group
immun
respect
crude
protein
contain
vlp
exhibit
virusneutr
antibodi
fold
fold
group
challeng
group
ten
mice
immun
commerci
vaccin
protect
perfectli
wherea
mice
immun
pb
die
due
infect
within
day
postchalleng
nine
ten
mice
immun
crude
protein
contain
vlp
protect
high
level
mice
immun
crude
protein
contain
vlp
surviv
figur
seen
figur
determin
twoway
anova
neutral
antibodi
pig
group
increas
fold
group
increas
fold
upon
inocul
singl
dose
crude
protein
contain
vlp
steadi
product
antibodi
maintain
two
week
decreas
dramat
three
week
immun
fold
group
group
show
increas
product
neutral
antibodi
primari
secondari
inocul
crude
protein
contain
vlp
neutral
antibodi
level
maintain
high
level
week
last
inocul
level
neutral
antibodi
group
fold
similar
group
group
swine
immun
commerci
emcv
vaccin
gener
higher
level
virusneutr
antibodi
titer
rang
fold
level
neutral
antibodi
maintain
five
week
final
inocul
contrast
swine
group
produc
detect
neutral
antibodi
sever
inject
site
reaction
observ
immun
swine
healthi
immun
period
viruslik
particl
promis
vaccin
candid
trigger
neutral
antibodi
respons
sinc
authent
mimic
viral
surfac
antigen
similar
parent
viru
addit
safe
devoid
infecti
genet
materi
vlp
produc
extens
human
veterinari
vaccin
candid
due
strong
immunogen
baculoviru
express
system
wide
use
gener
vlp
due
high
product
system
abil
achiev
rapid
product
scale
implement
vlp
success
gener
mani
picornavirida
famili
member
includ
enteroviru
polioviru
footand
mouth
diseas
viru
fmdv
previou
studi
engin
dna
vaccin
produc
vlp
confirm
vlp
antigen
exhibit
good
antigen
protect
immun
mice
present
studi
use
baculoviru
express
system
gener
emcv
vlp
verifi
capabl
express
fusion
protein
confirm
protein
correctli
process
proteas
protein
approxim
kda
previous
demonstr
data
also
show
abil
selfassembl
nm
nm
vlp
similar
morpholog
authent
viru
particl
porcin
emcv
show
tem
mice
immun
crude
protein
contain
vlp
crude
protein
contain
vlp
commerci
vaccin
display
differ
level
protect
viral
challeng
experi
correspondingli
linear
relationship
level
neutral
antibodi
protect
efficaci
emcv
vaccin
lethal
emcv
challeng
demonstr
vlpbase
vaccin
shown
confer
protect
anim
model
mani
viral
challeng
ie
enteroviru
foot
mouth
diseas
viru
influenza
viru
parvoviru
human
immunodefici
rotaviru
togeth
find
indic
vlp
dramat
effect
immunogen
assess
safeti
vlp
two
dose
crude
protein
includ
vlp
test
higher
dose
higher
lower
dose
immun
relat
clinic
sign
observ
group
second
immun
level
neutral
antibodi
similar
obtain
commerci
vaccin
effect
singledos
immun
induc
product
mainten
neutral
antibodi
swine
twice
immun
effect
induc
product
mainten
neutral
antibodi
swine
primari
immun
correspondingli
convent
inactiv
vaccin
also
administ
twice
second
boost
need
effect
induc
neutral
antibodi
product
neutral
antibodi
correl
protect
viral
infect
import
featur
effect
vaccin
addit
data
suggest
induct
high
level
emcv
specif
neutral
antibodi
may
essenti
protect
emcv
infect
studi
demonstr
twice
immun
vlp
vaccin
effect
induc
neutral
antibodi
thu
approach
may
signific
applic
novel
vaccin
strategi
control
emcv
futur
studi
plan
investig
vlp
vaccin
effici
safeti
effect
litter
size
pregnant
swine
base
result
present
studi
conclud
porcin
emcv
vlp
gener
use
baculoviru
express
system
safe
demonstr
good
antigen
immunogen
antigen
vaccin
emcv
vlp
indic
system
promis
vaccin
diseas
author
declar
compet
interest
hyj
whl
dja
particip
design
conduct
major
experi
studi
draft
manuscript
wsj
hwc
perform
swine
experi
analys
data
bh
hsl
perform
mice
experi
analys
data
author
read
approv
final
manuscript
